GlassScriptPhysician profile
Erin E Walczykowski
NPI 1316499825
$349,231.66
in general payments reported to CMS, 2019-2025
12 companies · $75K in 2025
The $75K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $103K · 2023: $81K · 2024: $61K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $27K · Consulting Fee: $16K · Food and Beverage: $7,681 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $167,330.50 |
| Travel and Lodging | $27,256.90 |
| Consulting Fee | $15,937.50 |
| Food and Beverage | $7,681.31 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $254,576.45 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $41,092.87 | 2021-2024 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $32,038.05 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $19,175.00 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $638.18 | 2021-2024 | Caplyta |
| Lundbeck LLC | $623.96 | 2022-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $452.37 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $275.53 | 2022-2023 | Austedo Xr, Austedo, Uzedy |
| Sunovion Pharmaceuticals INC. | $173.63 | 2022 | |
| Corium, LLC | $115.96 | 2022-2023 | Azstarys |
| Indivior INC. | $39.66 | 2022 | |
| Vanda Pharmaceuticals INC. | $30.00 | 2023 | Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Walczykowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.